Latest Asx News

Redivium Limited is progressing recapitalisation efforts and revising its UK lithium-ion battery recycling project plans amid ongoing ASX suspension. The company is engaging Australian investors to support reinstatement and updating feasibility studies following site changes.

Alvo Minerals has raised $2.26 million through a placement to accelerate drilling and exploration at its Palma Copper-Zinc Project in Brazil, including the promising new Touro Prospect.

Redivium Limited has advanced its battery recycling ambitions with a binding offtake agreement alongside strategic funding plans, despite ongoing ASX suspension. The company’s new partnership with WMC Energy BV marks a pivotal step toward commercialising its UK recycling facility.

PeopleIN Limited is set to divest its majority stake in Techforce Personnel, securing over a 100% return and strengthening its balance sheet to fuel future acquisitions.

Pioneer Credit has secured a further 15 basis point reduction on its $272.5 million senior finance facility, lowering its funding costs and reinforcing its commitment to sustainable business practices.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.

RareX Limited has signed a historic Mining Heritage Protection Agreement with the Jaru people, clearing a major hurdle for the Cummins Range rare earths project and paving the way for a Mining Lease.

Imugene Limited and JW Therapeutics have launched a strategic collaboration to combine oncolytic virus and CAR-T cell therapies, aiming to tackle refractory solid tumors through a pioneering 'mark and kill' approach.

HUB24 Limited showcased strong growth and strategic innovation at its 2025 Investor Strategy Day, highlighting market leadership and ambitious expansion plans across wealth management technology.

Ironbark Capital reported an 8.4% portfolio return for FY25 and announced plans to rebrand and introduce quarterly dividends to address its persistent discount to net tangible assets.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.